ImmuniCell (autologous γδ T lymphocytes) / TC Biopharm - LARVOL DELTA

A Simple and Robust Single-Step Method for CAR-Vδ1 γδT Cell Expansion and Transduction for Cancer Immunotherapy. (PubMed, Front Immunol) - "These Vδ1 cells can be virally transduced to express chimeric antigen receptors (CARs) using standard techniques, and the CAR-Vδ1 exhibit antigen-specific persistence, cytotoxicity and produce IFN-γ. Practicable, GMP-compatible engineered Vδ1 cell expansion methods will be crucial to the wide-spread clinical testing of these cells for oncology indications."

Journal • Oncology • IFNG • IL15 • NCAM1

[VIRTUAL] Therapeutic potential of allogeneic Gamma Delta T cell therapy in relapsed/refractory acute myeloid leukemia - Preliminary data from phase 1 study (AACR-II 2020) - P1 | "Prior to TCB002 infusion, patients underwent a 5-day standard lymphodepleting pre-conditioning treatment with fludarabine and cyclophosphamide... These preliminary results from a first-in-human dose escalation study highlight the encouraging safety profile and therapeutic potential TCB002 for patients with R/R AML. Achievement of CR and improvement of performance status post-treatment suggests a potential role for TCB002 as a bridge therapy. The trial remains open for enrolment."

P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

[VIRTUAL] Therapeutic potential of allogeneic gamma delta T cell therapy in relapsed/refractory acute myeloid leukaemia – preliminary data from a phase 1 study (BSH-I 2020) - P1 | "Prior to TCB002 infusion, patients underwent a 5-day standard lymphodepleting pre-conditioning treatment with fludarabine and cyclophosphamide...The trial remains open for enrolment. Dose escalation continues."

P1 data • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases • Transplantation

ImmuniCell® in Patients With Advanced Cancers (clinicaltrials.gov) - P2; N=8; Active, not recruiting; Sponsor: TC Biopharm; Recruiting ➔ Active, not recruiting; Phase classification: P2/3 ➔ P2; N=60 ➔ 8

Enrollment change • Enrollment closed • IO Biomarker • Phase classification • Biosimilar • Melanoma • Non Small Cell Lung Cancer • Renal Cell Carcinoma

γδ T Cells Are Required for M2 Macrophage Polarization and Resolution of Ozone-Induced Pulmonary Inflammation in Mice. (PubMed) - "Delayed restoration of normal lung architecture was also observed in TCRδ-/- mice. In summary, our data indicate that γδ T cells are required for the resolution of ozone-induced inflammation, likely because γδ T cells, through their secretion of IL-17A, contribute to changes in macrophage polarization that promote clearance of apoptotic cells."

Journal • Biosimilar • Immunology • Inflammation

Therapeutic potential of allogeneic gamma delta T cell therapy in relapsed/refractory acute myeloid leukaemia – preliminary data from a phase 1 study (BSH 2020) - P1 | "Prior to TCB002 infusion, patients underwent a 5-day standard lymphodepleting pre-conditioning treatment with fludarabine and cyclophosphamide...The trial remains open for enrolment. Dose escalation continues."

P1 data • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases

"Michael Leek (TC Biopharm) reckons gamma-delta T cell based allo product could get cost of goods down to $5,000/pt #CARTCREU" (@JacobPlieth)

Pricing

"TC Biopharm makes progress on gamma-delta T cell work, but best (CAR-T) is yet to come. Via @Vantageanalysis https://t.co/tZjUIAobU3 $BLUE $GILD" (@JacobPlieth)

Gamma Delta T Cells in AML (clinicaltrials.gov) - P; N=20; Recruiting; Sponsor: Royal Marsden NHS Foundation Trust

Clinical • New trial